NCT01621724View on ClinicalTrials.gov

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia

Interventions

GENETIC

WT1 TCR-transduced T cells

"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"

Trial Locations (2)

BS38 3AP

University Hospitals Bristol NHS Foundation Trust, Bristol

NW1 2PG

University College London Hospitals NHS Trust, London